Document:

Converted by EDGARwiz

  EXHIBIT 10.1
 

 AMENDMENT NO. 1 TO
 SHARE PURCHASE AGREEMENT
 

 This Amendment No. 1 to Share Purchase Agreement (this “Amendment”), dated October 25, 2011, by and among Par Pharmaceutical, Inc., a Delaware corporation (the “Buyer”), Edict Pharmaceuticals Private Limited, a company incorporated under the laws of India, having its registered office at 1/58, Pudupakkam Main Road, Pudupakkam, Kelambakkam – 603 103, Chennai, Tamilnadu, India (the “Company”), Clan Laboratories Private Limited, a company incorporated under the laws of India, having its registered office at 1/58, Pudupakkam Main Road, Pudupakkam, Kelambakkam – 603 103, Chennai, Tamilnadu, India (“Clan Laboratories”), Muthusamy Shanmugam, an individual (“M. Shanmugam”), Jaganathan Jayaseelan, an individual (“J. Jayaseelan”, and together with Clan Laboratories and M. Shanmugam, the “Major Sellers” and each, a “Major Seller”), Seema Suresh, an individual (“S. Suresh”), Thertha Investment & Portfolio Services Private Limited, a company incorporated under the laws of India, having its registered office at Flat No. 1, Prasanna Enclave, No. 30, Bharathi Avenue, 2nd Street, Kotturpuram, Chennai – 600085, Tamil Nadu, India (“TIPS,” collectively with Clan Laboratories,  J. Jayaseelan, M. Shanmugam and S. Suresh, the “Sellers,” and each individually, a “Seller”), and J. Jayaseelan, solely in his capacity as Sellers’ Representative.  Capitalized terms used but not defined herein shall have the meanings attributed to them in the Purchase Agreement (as defined below).
 

 W I T N E S S E T H:
 

 WHEREAS, the Buyer, the Company, the Sellers and the Sellers’ Representative, have entered into that certain Share Purchase Agreement, dated May 17, 2011 (the “Purchase Agreement”); and
 

 WHEREAS, in accordance with Section 12.3 of the Purchase Agreement, the parties desire to amend the Purchase Agreement as set forth herein.
 NOW, THEREFORE, in consideration of the premises herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows:
 

 1.
 Amendments to Purchase Agreement.
 (a)
 Section 2.2(b) of the Purchase Agreement is hereby amended by deleting the phrase “subject to Sections 2.3 and 12.5” and replacing it with the following: “subject to Section 12.5”.
 (b)
 Section 2.2(c) of the Purchase Agreement is hereby amended and restated as follows:
 

 - 1 -
 
 
 “(c)
 Additional Payments. In addition to the Closing Consideration, the Buyer shall pay up to a maximum of $12,000,001 as the balance of consideration for the Company Common Shares (“Additional Payments”), payable as, and subject to the satisfaction of the conditions and the achievements, set forth below:
 (i)
 If the FDA’s inspection of the Facility is successful as indicated by (A) a No Action Indicated Finding or a completed inspection without the issuance of a FDA Form 483, (B) an acknowledgement letter from the FDA stating that the Company’s response to any Form 483 issued in connection with such inspection is acceptable to the FDA, or (C) a Voluntary Action Indicated classification with recommendation for approval of any and all ANDA filings which were subject of the inspection, then Buyer shall pay:
 (1)
 $3,000,000 no later than the later of (x) sixty (60) days after any of the criteria set forth subsections (A) through (C) above is satisfied and (y) sixty (60) after the Closing Date; and 
 (2)
 $2,000,000 on the later of (x) five (5) business days after any of the criteria set forth in subsections (A) through (C) above is satisfied and (y) eighteen (18) months after the Closing Date.
 (ii)
 For each of the two products listed on Schedule 2.2 attached hereto and a third product to be agreed upon by the Buyer and the Seller’s Representative in writing (the “Third Product”), the Buyer shall pay $1,666,667 to the Sellers if a complete ANDA is accepted for filing by the FDA on or before the first anniversary of the Closing Date (or, with respect to the Third Product, the first anniversary of the date on which the identification of the Third Product is agreed if the Buyer and Sellers’ Representative have not reached agreement by the Closing Date), which amount shall be payable within five (5) business days after the applicable ANDA has been accepted for filing by the FDA.
 (iii)
 If complete ANDAs for all of the products listed on Schedule 2.2, the Third Product, and two additional products to be agreed upon by the Buyer and the Sellers’ 
 

 - 2 -
 
 Representative in writing (collectively, the “Requested ANDAs,” and each individually, a “Requested ANDA”) are accepted for filing by the FDA on or before the first anniversary of the Closing Date (or, if the Buyer and the Sellers’ Representative have not agreed on the Third Product or either of the two additional products by the Closing Date, the first anniversary of the date on which the identification of the final product is agreed), the Buyer shall pay $2,000,000 to the Sellers within five (5) business days after all of the Requested ANDAs have been accepted for filing.”
 (c)
 Section 2.3 of the Purchase Agreement is hereby deleted in its entirety and replaced with the following: “[Intentionally Omitted]”.
 (d)
 Schedule 2.5 to the Purchase Agreement is hereby replaced in its entirety with Schedule 2.5 attached hereto.
 (e)
 Section 6 of the Purchase Agreement is hereby amended by adding the following new section thereto:
  “6.19   Maximum Indebtedness.  The Company and the Major Sellers shall ensure that: 
 (a)   the aggregate amount of the Company Indebtedness (excluding any Indebtedness incurred by the Company after the date hereof, with the prior written consent of the Buyer, to purchase the materials and capital assets necessary for the Company to develop products under the Supply Agreement (the “Capex Loans”)), as set forth in the applicable Payoff Letters, shall not exceed the rupee equivalent of $4,300,000; and
 (b)   the aggregate amount of the Capex Loans (including all interest and fees thereon) on the Closing Date, as set forth in the applicable Payoff Letter, shall not exceed the rupee equivalent of the sum of (i) $800,000 (for a portion of the capital and material expenditures set forth on Schedule 2.3(c) of the Purchase Agreement) plus (ii) any additional amount approved in writing by Buyer after the date hereof in respect of the purchase of materials or capital assets (the “Approved Capex Loan Amount”).
 (f)
 Section 9.1(b) of the Purchase Agreement is hereby amended and restated as follows:
 

 - 3 -
 
 “by either the Buyer or the Company, if the Closing shall not have occurred by December 19, 2011, upon written notice by such terminating party; provided that at the time such notice is given, a material breach of this Agreement by such terminating party shall not be the principal reason for the failure of the Closing to occur;”
 (g)
 Section 9.1(d) of the Purchase Agreement is hereby amended by adding the following new subsection thereto:
 “(iii) that certain Settlement Agreement and Mutual Release and Covenant Not to Sue, dated October 20, 2011, among Buyer, Par Pharmaceutical Companies, Inc., a Delaware corporation, the Company, Clan Laboratories, Ordain Healthcare Private Limited, a company organized under the laws of India, M. Shanmugam, J. Jayaseelan, Gavis Pharma LLC, a Delaware limited liability company, Novel Laboratories, Inc., a Delaware corporation, and Veerappan Subramanian, an individual, is terminated.”
 (h)
 Section 10.2(a) of the Purchase Agreement is hereby amended by adding the following new subsection thereto:
 “(iv)   The existence of any Company Indebtedness, including Capex Loans, in excess of the maximum amounts specified in Section 6.19 on the Closing Date.”
 2.
 Miscellaneous.
 (a)
 Governing Law.  This Amendment shall be governed by and construed in accordance with the laws of the State of New York (without giving effect to the conflict of laws principles thereof that would result in the application of the law of a different jurisdiction). 
 (b)
 Effect on Transaction Documents.  The terms and provisions set forth in this Amendment shall amend and supersede the terms and provisions of the Purchase Agreement solely to the extent set forth in Section 1 above, and except as expressly amended in Section 1 above, the Purchase Agreement shall remain in full force and effect.  All references in the Purchase Agreement and the Ancillary Agreements to the Purchase Agreement shall be deemed to refer to such agreement as amended by this Amendment.
 (c)
 Counterparts.  This Amendment may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
 

  

 

 

  - 4 -
 
 
  IN WITNESS WHEREOF, the parties have executed and delivered this Amendment as of the date first above written.
 

 	 	
	 Par Pharmaceutical, Inc.
 

 

 By:/s/ Paul V. Campanelli
      Name: Paul V. Campanelli
      Title:  President – Par Pharmaceutical
 

 

 

 Clan Laboratories Pvt. Ltd.
 

 

 

 By:/s/ Jaganathan Jayaseelan
       Name: Jaganathan Jayaseelan
       Title:   Director
 

 

 /s/ Jaganathan Jayaseelan
 Jaganathan Jayaseelan
 

 

 

 

 /s/ Muthusamy Shanmugam
 Muthusamy Shanmugam
 

 

 

	 Edict Pharmaceuticals Private Limited
 

 

 By:/s/ Jaganathan Jayaseelan
      Name: Jaganathan Jayaseelan
      Title:  President
 

 

 

 Thertha Investment & Portfolio Services Private Limited
 

 

 By:/s/ Suresh Bhojraj
       Name: 
       Title: 
 

 

 /s/ Seema Suresh
 Seema Suresh
 

 

 

 

 Jaganathan Jayaseelan, as Sellers’ Representative
 

 

 By: /s/ Jaganathan Jayaseelan
      Name: 
      Title:

 

 

 

 

 

 

 

 

 

 

 

 

 [Signature Page to Amendment No. 1 to Share Purchase Agreement]
 

 - 5 -SM - 10.1

EXHIBIT 10.1

SM ENERGY COMPANY

PERFORMANCE STOCK UNIT AWARD AGREEMENT

This Performance Stock Unit Award Agreement (the “Agreement”) is made effective as of September 6, 2011 (the “Award Date”), by and between SM Energy Company, a Delaware corporation (the “Company”), and [Name] (the “Participant”) to whom performance stock units have been awarded under the Company's Equity Incentive Compensation Plan, as amended (the “Plan”).
Effective as of July 1, 2011, the Company made an award of Performance Units to Participant pursuant to a Performance Stock Unit Award Agreement (the “Prior Award Agreement”).  This Agreement and the award of Performance Units hereunder is intended to replace and supersede the Prior Award Agreement and the award of Performance Units thereunder.  Accordingly, the Company and Participant hereby agree to terminate the Prior Award Agreement, and the Participant hereby waives, surrenders and releases the Company from any claim related to the Prior Award Agreement or the Performance Units related thereto.
Pursuant to the terms of the Plan and this Agreement, as of the Award Date, the Company makes an award (the “Award”) to the Participant of [Number] performance stock units (the “Performance Units”).  Capitalized terms used but not defined in this Agreement shall have the meanings given to them in the Plan.
ARTICLE I
PERFORMANCE UNITS
1.1        Performance Units and Performance Period.  The Performance Units represent the right to receive, upon the payment of the Performance Units pursuant to Section 1.4 hereof after the completion of the Performance Period (as defined below), a number of shares of the Company's common stock, $.01 par value per share (sometimes referred to herein as the “Common Stock”), that will be calculated as set forth in Section 1.2 below based on the extent to which the Company's Performance Criteria (as defined in Section 1.2) have been achieved and the extent to which the Performance Units have vested.  Any Common Stock that is issued pursuant to any provision of this Agreement may be referred to in this Agreement as a “Share” or “Shares.”  Such actual number of Shares that may be issued upon payment of the Performance Units may be from zero (0) to two (2.0) times the number of Performance Units granted on the Award Date.  The number of Performance Units granted herein may be referred to as the “target” number of Shares.  The performance period (the “Performance Period”) for the Performance Units shall be the three-year period beginning on July 1, 2011 and ending on June 30, 2014.

1.2        Determination of Number of Shares Earned.

(a)Performance Criteria.  The actual number of Shares that may be earned from the Performance Units and issued upon payment of the Performance Units after completion of the Performance Period shall be based upon the Company's achievement of performance criteria (the “Performance Criteria”) established by the Compensation Committee of the Board of Directors of the Company (the “Committee”) for the Performance Period in accordance with the terms of the Plan and as set forth below and reflected in the payout matrix (the “Payout Matrix”) attached as Appendix A hereto and discussed further in subsection (d) hereof.  The 

Performance Criteria for the calculation of the actual number of Shares to be issued upon payment of the Performance Units as reflected in the Payout Matrix are based on a combination of (i) the absolute measure of the cumulative total shareholder return (“TSR”) and associated Compound Annual Growth Rate (“CAGR”) of the Company for the Performance Period, and (ii) the relative measure of the Company's TSR and CAGR for the Performance Period compared with the cumulative TSR and CAGR of the Peer Companies (as defined below) for the Performance Period as reflected in the Company's Performance Share Plan Peer Group Custom Index (the “Custom Index”) to be specifically prepared by Standard & Poor's, a division of The McGraw-Hill Companies, Inc. (“S&P”), for the purpose of administering the Company's Long-Term Incentive Plan.

(b)Calculation of TSR and CAGR.  The TSR and CAGR of the Company and the Peer Companies for the Performance Period shall be calculated in accordance with the methodology utilized by S&P with respect to the Custom Index.

(c)Peer Companies and Custom Index.  The “Peer Companies” to be reflected in the Custom Index shall consist of the constituents of the Oil & Gas Exploration & Production GIC Sub-Industry Group in the S&P SmallCap 600 Index and the S&P MidCap 400 Index, excluding the Company.  The Custom Index will be equally weighted, and will be adjusted to include the dividend payments of the constituents of the Custom Index.  The Custom Index will be rebalanced on a quarterly basis, and will also be rebalanced whenever there are additions and deletions to the S&P SmallCap 600 and the S&P MidCap 400 indices.  The Custom Index is the exclusive property of S&P.  The Company has contracted with S&P to maintain and calculate the Custom Index.  S&P shall have no liability for any errors or omissions in calculating the Custom Index.

(d)Payout Matrix.  The Payout Matrix attached as Appendix A hereto sets forth the possible multipliers, which range from zero percent (0%) to two hundred percent (200%), which may be applied to the number of vested Performance Units to determine the actual number of Shares to be issued upon payment of the vested Performance Units after the completion of the Performance Period.  The final multiplier (the “Final Multiplier”) shall be determined by the Committee after the completion of the Performance Period based on the two variables that comprise the Performance Criteria, related to (i) the Company's TSR and CAGR for the Performance Period, and (ii) the Peer Companies' TSR and CAGR for the Performance Period as reflected in the Custom Index.  Subject to Section 1.2(e), the number of Shares, if any, that shall be issued to the Participant upon payment of the Performance Units shall be calculated as an amount equal to (A) the number of Performance Units that have vested in accordance with Section 1.3 or Section 1.6 hereof, multiplied by (B) the Final Multiplier, as determined by the Committee in accordance with the Payout Matrix (such number of Shares, the “Payout Shares”).There shall be no rounding of variables or extrapolation of variables between data points within the Payout Matrix, and the data point for which the associated variables equal or exceed the target variables for such data point, but do not result in qualification for another higher data point, shall be utilized with respect to the Final Multiplier.  Any fractional Shares which would otherwise result from application of the Final Multiplier shall be rounded up to the nearest whole Share of Common Stock.  

(e)Payout Value Limit.  Notwithstanding any other provision of this Agreement, under no circumstances shall (i) the product of (A) the number of Payout Shares as calculated in accordance with the Payout Matrix under the provisions of Section 1.2(d), 

multiplied by (B) the per share closing price of the Company's Common Stock on June 30, 2014, as reported by the principal exchange or market on which the Company's Common Stock is then traded (the “Payout Closing Price”) (with such product referred to as the “Payout Matrix Value”), exceed (ii) the product of (C) the number of Performance Units multiplied by (D) $449 (with such product referred to as the “Payout Value Limit”).  If the Payout Matrix Value would otherwise exceed the Payout Value Limit, then the number of Payout Shares shall be reduced to an amount equal to (x) the Payout Value Limit divided by (y) the Payout Closing Price, with any fractional Shares which would otherwise result from such computation to be rounded up to the nearest whole Share of Common Stock.

1.3        Vesting of Performance Units.

(a)Vesting.  Subject to the provisions contained herein, the Performance Units shall vest over the Performance Period as follows (the “PSU Vesting Schedule”):

1/7th (approximately 14.3%) on July 1, 2012
2/7ths (approximately 28.6%) on July 1, 2013
4/7ths (approximately 57.1%) on July 1, 2014

In addition, the Performance Units may become fully vested or be forfeited under certain circumstances specified in this Agreement.  As of the Award Date, the Participant must be an employee of the Company or a subsidiary thereof.  If the Participant ceases to be an employee of the Company or a subsidiary thereof prior to the vesting of all of the Performance Units pursuant to the PSU Vesting Schedule, the Participant shall forfeit the remaining unvested Performance Units under the Award, except as otherwise provided in this Section 1.3 and Section 1.6.
(b)Continued Vesting Upon Early Retirement.  The Performance Units shall, notwithstanding any other provisions of this Section 1.3, continue to vest according to the PSU Vesting Schedule after the termination of the Participant's employment with the Company or a subsidiary thereof if (i) such termination is the result of the Participant's retirement from the Company or a subsidiary thereof upon the Participant's having both reached the age of sixty (60) and completed twelve (12) years of service with the Company or a subsidiary thereof, and (ii) the Participant does not after such early retirement become employed on a full-time basis by a competitor of the Company prior to the earlier of the payment of the Performance Units or the Participant's reaching the age of sixty-five (65).  Any such continued vesting of the Performance Units pursuant to this Section 1.3(b) will not result in an acceleration of the PSU Payment Date (as defined in Section 1.4), since the number of Shares earned from the Performance Units shall be calculated after the completion of the Performance Period.

(c)Acceleration Upon Death, Total Disability or Normal Retirement.  The Performance Units shall become fully vested, notwithstanding any other provisions of this Section 1.3, upon termination of the Participant's employment with the Company or a subsidiary thereof because of death, Total Disability (as defined below), or retirement upon reaching the Company's normal retirement age of sixty-five (65).  Any such acceleration of the vesting of the Performance Units pursuant to this Section 1.3(c) will not result in an acceleration of the PSU Payment Date, since the number of Shares earned from the Performance Units shall be calculated after the completion of the Performance Period.  For purposes of this Agreement, “Total Disability” means a medically determinable physical or 

mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than 12 months, by reason of which the Participant is unable to engage in any substantial gainful activity or is receiving income replacement benefits for a period of not less than three months under an accident and health plan covering employees of the Company.

(d)Termination for Cause.  Notwithstanding any other provisions of this Section 1.3, the Participant shall forfeit all Performance Units under this Award, including those that have previously vested, upon the termination of the employment of the Participant by the Company or a subsidiary thereof prior to the completion of the Performance Period for cause, which term is specifically not capitalized as such term is in Section 1.6(a) of this Agreement, it being the specific intent of the Company and the Participant that “cause” in this instance shall be broadly defined as any event, action, or inaction by the Participant that would reasonably be the basis for an employer to terminate the employment of the affected individual. 

1.4        Payment of Performance Units.  Following the last day of the Performance Period and prior to the payment of the earned and vested Performance Units on or about the PSU Payment Date, the Committee shall determine, and certify in writing to the extent deemed necessary or advisable or as required to comply with Section 162(m) of the Internal Revenue Code of 1986, as amended (the “Code”), (i) the extent to which the Performance Criteria have been achieved over the Performance Period, and (ii) the Final Multiplier.  Subject to Section 1.2(e), the Final Multiplier shall then be applied to the number of vested Performance Units to determine the number of Payout Shares (also sometimes referred to herein as the “Earned Shares”), if any, to be issued to the Participant in payment of the Performance Units.  The determination of the Earned Shares by the Committee shall be binding on the Participant and conclusive for all purposes.  The Earned Shares, if any, shall be issued to the Participant in payment of the Performance Units on or about July 3, 2014 (the “PSU Payment Date”).  Upon the payment of the Performance Units, the Company shall deliver to the Participant evidence of book-entry Shares or a certificate for the number of Shares issued to the Participant in payment of the Performance Units.  The Earned Shares shall not be subject to any holding or transfer restrictions after payment of the Performance Units.

1.5        Transfer Restrictions for Unpaid Performance Units.  Performance Units that have not been paid shall not be transferable by the Participant, and the Participant shall not be permitted to sell, transfer, pledge, assign, or otherwise alienate or encumber such Performance Units or the Shares issuable in payment thereof, other than (i) to the person or persons to whom the Participant's rights under such Performance Units pass by will or the laws of descent and distribution, (ii) to the spouse or the descendants of the Participant or to trusts for such persons to whom or which the Participant may transfer such Performance Units by gift, (iii) to the legal representative of any of the foregoing, or (iv) pursuant to a qualified domestic relations order as defined under Section 414(p) of the Code or a similar order or agreement pursuant to state domestic relations law (including a community property law) relating to the provision of child support, alimony payments, or marital property rights to a spouse, former spouse, child, or other dependent of the Participant.  Any such transfer shall be made only in compliance with the Securities Act of 1933 and the requirements therefor as set forth by the Company.  Any attempted transfer in contravention of the foregoing provisions shall be null and void and of no effect.

1.6        Change of Control Termination.

(a)Vesting upon Change of Control Termination.  Notwithstanding any other 

provision of this Agreement, the Performance Units shall become fully vested upon a Change of Control Termination.  For purposes of this Agreement, a “Change of Control Termination” occurs upon the termination of the Participant's employment with the Company or a subsidiary thereof in the event that (i) a Change of Control (as defined in the Plan) of the Company occurs, and (ii) the Participant's employment with the Company or a subsidiary thereof is subsequently terminated without Cause (as defined below) or the Participant terminates his or her employment with the Company or a subsidiary thereof for Good Reason (as defined below), and such termination of employment occurs (x) within 30 months of the Change of Control and (y) prior to the normal completion of vesting of the Performance Units at the end of the Performance Period.  The normal vesting and payment provisions in Article I of this Agreement shall not be affected by the first sentence of this subsection if a Change of Control of the Company occurs but there is not also a Change of Control Termination with respect to the Participant's employment with the Company or a subsidiary thereof.  If the Participant has entered into a separate written Change of Control Executive Severance Agreement or Change of Control Severance Agreement (with either to be subsequently referred to herein as a “Change of Control Severance Agreement”) with the Company, the terms “Cause” and “Good Reason” used herein shall have the meanings set forth in such Change of Control Severance Agreement.  If the Participant has not entered into a separate written Change of Control Severance Agreement, the terms “Cause” and “Good Reason” used herein shall have the meanings set forth in the Company's Change of Control Severance Plan (the “Change of Control Severance Plan”).

(b)Payment upon Change of Control Termination.  Notwithstanding any other provisions of this Agreement to the contrary, in the event of a Change of Control Termination with respect to the Participant's employment with the Company or a subsidiary thereof as set forth in Section 1.6(a) above, the vested Performance Units shall be paid in accordance with this Section 1.6(b).  In the event of a Change of Control Termination, the Committee shall determine the extent to which the Performance Criteria have been achieved and the Final Multiplier to apply to the vested Performance Units by utilizing the same method as set forth in Section 1.2 hereof; provided, however, that the Performance Period for the calculation of the TSR and CAGR of the Company and the Peer Companies to obtain the Final Multiplier shall be shortened to end as of the effective date of the Change of Control.  Subject to Section 1.2(e), the Final Multiplier shall then be applied to the number of vested Performance Units to calculate the number of Earned Shares, if any, that the Participant is entitled to in payment of the Performance Units.  In the event of a Change of Control Termination, any Earned Shares shall be paid to the Participant in payment of the Performance Units either in Shares or in cash of equivalent value, as determined by the Committee or other duly authorized administrator of the Plan, in its discretion, within thirty (30) days following the effective date of the Change of Control Termination; provided, however, that the time and manner of such payment shall comply with Section 409A of the Code as referred to in Section 2.11 of this Agreement.

(c)Controlling Documents for Change of Control Termination.  To the extent that the Participant is subject to either a written Change of Control Severance Agreement or the Change of Control Severance Plan, the terms and conditions of such Change of Control Severance Agreement or Change of Control Severance Plan, as applicable, shall also apply to this Award in the event of a Change of Control Termination; provided, however, that with respect to the Performance Units under this Award, the terms of the Plan and this Agreement shall control in the event of any inconsistency between their terms and the terms of the Change of Control Severance Agreement or the Change of Control Severance Plan.

ARTICLE II
GENERAL PROVISIONS
2.1        Adjustments Upon Changes in Capitalization.  In the event that a stock split, stock dividend, or other similar change in capitalization of the Company occurs, the number and kind of Shares that may be issued under this Agreement and that have not yet been issued shall be proportionately and appropriately adjusted.

2.2        No Dividend Equivalents or Stockholder Rights Until Shares Issued.  The Performance Units shall not be credited with Dividend Equivalents.  In addition, the Participant shall have no voting, transfer, liquidation, or other rights of a holder of Shares with respect to the Performance Units until such time as Shares, if any, have been issued by the Company to the Participant in payment of the Performance Units.  Until the Performance Units are paid or terminated, they will represent only bookkeeping entries by the Company to evidence unfunded and unsecured obligations of the Company.

2.3        Notices.  Any notice to the Participant relating to this Agreement shall be in writing and delivered in person or by mail, fax, or email transmission to the address or addresses on file with the Company.  Any notice to the Company shall be addressed to it at its principal office, and be specifically directed to the attention of the Secretary.  Anyone to whom a notice may be given under this Agreement may designate a new address by notice to that effect.

2.4        Benefits of Agreement.  This Agreement shall inure to the benefit of and be binding upon each successor of the Company and the Participant's heirs, legal representatives, and permitted transferees.  This Agreement and the Plan shall be the sole and exclusive source of any and all rights that the Participant and the Participant's heirs, legal representatives, and permitted transferees may have with respect to this Award, the Performance Units, and the Plan.

2.5        Resolution of Disputes.  Any dispute or disagreement that arises under, or is a result of, or in any way relates to, the interpretation, construction, or applicability of this Agreement shall be resolved as determined by the Committee, or the Board of Directors of the Company (the “Board”), or by any other committee appointed by the Board for such purpose.  Any determination made hereunder shall be final, binding, and conclusive for all purposes.

2.6        Controlling Documents.  The provisions of the Plan are hereby incorporated into this Agreement by reference.  In the event of any inconsistency between this Agreement and the Plan, the Plan shall control. 

2.7        Amendments.  This Agreement may be amended only by a written instrument executed by both the Company and the Participant.

2.8        No Right of Participant to Continued Employment.  Nothing contained in this Agreement or the Plan shall confer on the Participant any right to continue to be employed by the Company or any subsidiary thereof, or shall limit the Company's right to terminate the employment of the Participant at any time; provided, however, that nothing contained in this Agreement shall affect any separate contractual provisions that exist between the Participant and the Company or its subsidiaries with respect to the employment of the Participant.

2.9        Vesting Dates and Payment Dates.  In the event that any vesting date, payment date, or any other measurement date with respect to this Award does not fall on a normal business day, such date shall be deemed to occur on the next following normal business day.

2.10    Tax Withholding.  The Company may make such provisions and take such steps as it deems necessary or appropriate for the withholding of any taxes that the Company is required by law or regulation of any governmental authority, whether Federal, state, or local, to withhold in connection with the Performance Units or Shares subject to this Agreement.  The Participant shall elect, prior to any tax withholding event related to this Award and at a time when the Participant is not aware of any material nonpublic information about the Company and the Participant would be permitted to engage in a transaction in the Company's securities under the Company's Securities Trading Policy, whether the Participant will satisfy all or part of such tax withholding requirement by paying the taxes in cash or by having the Company withhold Shares having a fair market value equal to the minimum statutory withholding that may be imposed on the transaction (based on minimum statutory withholding rates for Federal, state, and local tax purposes, as applicable, that are applicable to such transaction).  The Participant's election shall be irrevocable, made in writing, signed by the Participant, and shall be subject to any restrictions or limitations that the Committee, in its sole discretion, deems appropriate.

2.11    Compliance with Section 409A of the Code.  Notwithstanding any provision in this Agreement to the contrary, to the extent that this Agreement constitutes a nonqualified deferred compensation plan or arrangement to which Section 409A of the Code applies, the administration of this Award (including the time and manner of payments under the Award and this Agreement) shall comply with Section 409A of the Code.  In connection therewith, any payment to the Participant with respect to the Award under this Agreement which Section 409A(a)(2)(B)(i) of the Code indicates may not be made before the date which is six months after the date of the Participant's separation from employment service (the “Section 409A Six-Month Waiting Period”), as a result of the fact that the Participant is a specified key employee referred to in Section 409A(a)(2)(B)(i) of the Code, shall not occur or be made during the Section 409A Six-Month Waiting Period but rather shall be delayed, if such payment would otherwise occur during the Section 409A Six-Month Waiting Period, until the expiration of the Section 409A Six-Month Waiting Period.

2.12    Personal Data.  The Participant hereby consents to the collection, use, and transfer, in electronic or other form, of the Participant's personal data as described in this Agreement by and among, as applicable, the Company and its affiliates for the exclusive purpose of implementing, administering, and managing the Participant's participation in the Plan.  The Company holds, or may receive from any agent designated by the Company, certain personal information about the Participant, including, but not limited to, the Participant's name, home address and telephone number, date of birth, social security insurance number or other identification number, salary, nationality, job title, any shares of Common Stock held, details of this Award and any other rights to shares of Common Stock awarded, canceled, exercised, vested, unvested, or outstanding in the Participant's favor, for the purpose of implementing, administering, and managing the Plan, including complying with applicable tax and securities laws (the “Personal Data”).  The Personal Data may be transferred to any third parties assisting in the implementation, administration, and management of the Plan.  The Participant authorizes such recipients of the Personal Data to receive, possess, use, retain, and transfer the Personal Data, in electronic or other form, for the purposes described above.  The Participant may, at any time, view the Personal Data, request additional information about the storage and processing of the Personal Data, require any necessary amendments to the Personal Data, or refuse or withdraw the consents herein, in any case without cost, by contacting the Secretary of the Company in writing.  Any such refusal or withdrawal of 

the consents herein may affect the Participant's ability to participate in the Plan.

2.13    Electronic Delivery of Documents.  The Company may, in its sole discretion, deliver any documents related to this Award, or any future awards that may be granted under the Plan, by electronic means, or request the Participant's consent to participate in the Plan or other authorizations from the Participant in connection therewith by electronic means.  The Participant hereby consents to receive such documents by electronic delivery and, if requested, to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.

2.14    Receipt of Award and Related Documents.  The Participant hereby acknowledges the receipt, either directly or electronically, of the Award, a copy of the Plan, and a prospectus for the Plan.

2.15    Execution and Counterparts.  This Agreement may be executed in counterparts.  Execution of a written instrument for this Agreement may be evidenced by any appropriate form of electronic signature or affirmative email or other electronic response attached to or logically associated with such written instrument, which is executed or adopted by a party with an indication of the intention by such party to execute or adopt such instrument for purposes of execution thereof.

IN WITNESS WHEREOF, the Company and the Participant have caused this Performance Stock Unit Award Agreement to be entered into effective as of the Award Date.
COMPANY:
SM ENERGY COMPANY,
a Delaware corporation
By: /s/ John R. Monark                                                
Printed Name:  John R. Monark
Title:  Vice President, Human Resources
Date Signed:  September 6, 2011

PARTICIPANT:
Signature: ___________________________________________

Printed Name:  ________________________________

APPENDIX A

PAYOUT MATRIX FOR PERFORMANCE UNITS

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}]]